|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In MSRs, different immunophenotypes were distributed rather equally (Ten<sup>+</sup>Fn<sup>+</sup>Gal-1<sup>+</sup>=24%; Ten<sup>-</sup>Fn<sup>+</sup>Gal-1<sup>-</sup>=36%; Ten<sup>-</sup>Fn<sup>-</sup>Gal-1<sup>-</sup>=33%), differing to the results in tumors (p<0.05).
|
29491051 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Title compounds were tested in vitro against a panel of six human tumor cell lines, named A549 (non-small cell lung), HBL-100 (breast), HeLa (cervix), SW1573 (non-small cell lung), T-47D (breast) and WiDr (colon), and the results were compared with steroidal chemotherapeutic agents (abiraterone and galeterone); the A-ring of the steroidal backbone, the nature of the heterocycle and the N-substituents proved to be essential motifs for establishing structure-activity relationships concerning not only the potency but also the selectivity against tumor cell lines.
|
29172080 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The median time of tumor growth delay after 6 Gy irradiation was one week in tumors without galectin-1 expression, regardless of anginex administration.
|
29355463 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical (IHC) staining and CD34-periodic acid-Schiff double stain were used to investigate Gal-1 expression and VM in paraffin-embedded sections from 127 patients with GC of all tumor stages.
|
29881296 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We had previously identified up-regulation of Gal-1 in preclinical models of aggressive neuroblastoma (NB), the most common extracranial tumour of childhood.
|
29498681 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Galectin-1-based tumour-targeting for gold nanostructure-mediated photothermal therapy.
|
28540812 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The upregulation of <i>THBS2</i>, <i>COX7A1</i> and <i>LGALS1/galectin-1</i> in stroma-high tumors was validated in The Cancer Genome Atlas [corrected].
|
30140386 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Its involvement in cell proliferation, migration, invasion and tumor growth also intimate functional involvement of galectin-1 in the progression of thyroid carcinoma, suggesting its potential as a therapeutic target.
|
28677745 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we assessed the ability of non-peptidic galectin-1 inhibitor OTX008 to improve tumor oxygenation levels via tumor vessel normalization as well as tumor growth inhibition in two human HNSCC tumor models, the human laryngeal squamous carcinoma SQ20B and the human epithelial type 2 HEp-2.
|
29232825 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Oral administration of SKLB-850 considerably suppressed the tumor growth in BCL xenograft models (Ramos and HBL-1) in a dose-dependent manner.
|
29340070 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy.
|
28450700 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In patients with chronic lymphocytic leukemia (CLL) and classical Hodgkin lymphoma (cHL), high levels of Gal-1 within the tumor microenvironment were associated with worse disease state or poor outcome.
|
28435287 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, Gal-1 makes a crucial contribution to the pathogenesis of gastrointestinal malignancies, favoring tumor development, aggressiveness, metastasis, immunosuppression and angiogenesis.
|
28839427 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We observed that detachment from monolayer culture and growth as tumor spheroids was accompanied by changes in glucose metabolism, endogenous ROS levels, galectin-1 and glucose transporter GLUT1 protein levels.
|
28545086 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, Galectin-1 overexpression in PSCs was strongly associated with increased expression of EMT markers in both the orthotopic xenograft tumor in the pancreas and in metastatic lesions of naked mice.
|
29156810 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We were able to show that both tumor and stroma staining of Gal-1 could serve as negative prognostic factors for ovarian cancer.
|
28594391 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Gal-1 expression and T cell apoptosis were evaluated in 6 high-power fields (3 in the tumour and 3 in the stroma).
|
28108653 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that Gal1 and TGF-β1 might function coordinately within the HCC microenvironment to regulate tumor growth, invasion, metastasis, and angiogenesis.
|
26551914 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our previous cohort investigation showed that galectin-1 is associated with tumor invasiveness and is a possible independent prognostic marker of urinary bladder urothelial carcinoma.
|
27440446 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Authors have shown galectin-1 (Gal-1) and 3 playing roles in tumour angiogenesis and fibrosis, which were correlated with poor prognosis in patients with MPN.
|
27402956 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Twenty diagnostic protein signals were found characteristic for specific tumors (p ≤ 0.05), amongst them acyl-CoA-binding protein (m/z 11 162), macrophage migration inhibitory factor (m/z 12 350), thioredoxin (m/z 11 608) and galectin-1 (m/z 14 633) were assigned.
|
27174013 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a potential diagnostic application, radiolabeled antibodies showed specific targeting of galectin-1 positive tumors.
|
27062254 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review discusses the role of galectin-1 in the tumor microenvironment.
|
27649167 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Galectin-1 (Gal-1), a marker of CAFs, was previously reported to be associated with tumorigenesis and metastasis of various types of tumors.
|
27025601 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Four weeks later, nude mice were killed and tumor weight and diameter was measured. mRNA and protein expression of Galectin-1 in A549/DDP cells was higher than that in A549 cells. mRNA and protein expression of Galectin-1 in A549/DDP/I cells was lower than that in A549/DDP cells.
|
27392028 |
2016 |